MedTrace Logo

Intralipid Versus SMOFlipid in HPN Patients

NCT03773237 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-16

No results posted yet for this study

Summary

This study will randomize all patients who are new to the Mayo Clinic HPN team to either standard lipid emulsion (Intralipid) or SMOFLipid.

Conditions

  • Short Bowel Syndrome
  • Intestinal Fistula
  • Crohn Disease
  • Intestinal Obstruction

Interventions

DIETARY_SUPPLEMENT

SMOFLipid

SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.

DIETARY_SUPPLEMENT

Intralipid

Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid

Sponsors & Collaborators

Principal Investigators

  • Manpreet S Mundi, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2023-12-01
Completion
2024-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03773237 on ClinicalTrials.gov